Company intelligence / Profile preview
Antares Therapeutics
Boston, Massachusetts, United Statesantaresrx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Antares Therapeutics, a Scorpion Therapeutics spin-out, is developing a pipeline of small molecule precision medicines targeting previously undruggable proteins in cancer and other serious diseases; its lead candidate is expected to enter clinical trials in 2026. The company retains rights to milestone payments and royalties from two clinical-stage EGFR inhibitors for non-small cell lung cancer, now developed by Pierre Fabre[1][2][3][4][5].
- Therapeutic areas
- OncologyOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
AstraZeneca (collaboration on targeting transcription factors)Pierre Fabre Laboratories (EGFR inhibitors, out-licensed)
Beyond the preview
Go deeper on Antares Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antares Therapeutics.